ATE401896T1 - Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern - Google Patents

Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern

Info

Publication number
ATE401896T1
ATE401896T1 AT99955428T AT99955428T ATE401896T1 AT E401896 T1 ATE401896 T1 AT E401896T1 AT 99955428 T AT99955428 T AT 99955428T AT 99955428 T AT99955428 T AT 99955428T AT E401896 T1 ATE401896 T1 AT E401896T1
Authority
AT
Austria
Prior art keywords
sulphamat
methoxyestron
pharmaceutical compositions
necrosis factor
tumor necrosis
Prior art date
Application number
AT99955428T
Other languages
English (en)
Inventor
Michael Reed
Barry Potter
Original Assignee
Sterix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812535.4A external-priority patent/GB9812535D0/en
Priority claimed from GBGB9910167.7A external-priority patent/GB9910167D0/en
Application filed by Sterix Ltd filed Critical Sterix Ltd
Application granted granted Critical
Publication of ATE401896T1 publication Critical patent/ATE401896T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT99955428T 1998-06-10 1999-06-10 Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern ATE401896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812535.4A GB9812535D0 (en) 1998-06-10 1998-06-10 Composition
GBGB9910167.7A GB9910167D0 (en) 1999-04-30 1999-04-30 Composition

Publications (1)

Publication Number Publication Date
ATE401896T1 true ATE401896T1 (de) 2008-08-15

Family

ID=26313837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955428T ATE401896T1 (de) 1998-06-10 1999-06-10 Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern

Country Status (9)

Country Link
US (1) US6676934B1 (de)
EP (1) EP1085876B1 (de)
JP (1) JP2002517449A (de)
AT (1) ATE401896T1 (de)
AU (1) AU765386B2 (de)
CA (1) CA2334119C (de)
DE (1) DE69939171D1 (de)
ES (1) ES2310943T3 (de)
WO (1) WO1999064013A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127473A1 (en) * 1996-12-05 2004-07-01 Reed Michael John Compound
US7078395B1 (en) 1999-06-16 2006-07-18 Sterix Limited Methods for treating or preventing cancer by preventing, inhibiting or arresting cell cycling
IL145995A0 (en) 1999-04-30 2002-07-25 Sterix Ltd Use
GB9913536D0 (en) * 1999-06-10 1999-08-11 Sterix Ltd Use
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
FR2806303B1 (fr) * 2000-03-17 2002-09-27 Inst Nat Sante Rech Med Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments
US20020106348A1 (en) * 2000-07-12 2002-08-08 Peng Huang Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
WO2002015910A1 (en) * 2000-08-18 2002-02-28 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
GB0113920D0 (en) 2001-06-07 2001-08-01 Sterix Ltd Composition
WO2004000345A1 (ja) * 2002-06-19 2003-12-31 Takeda Pharmaceutical Company Limited 骨・関節疾患の予防・治療剤
DE10307103A1 (de) 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate
DE10307105A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte 18a-Homoestra-1,3,5(10)-trien-3-yl sulfamate
DE10307104A1 (de) 2003-02-19 2004-09-23 Schering Ag Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate
ES2339450T3 (es) * 2003-03-24 2010-05-20 Sterix Limited Derivados de estrogenos como inhibidores de esteroide sulfatasa.
GB0306717D0 (en) * 2003-03-24 2003-04-30 Sterix Ltd Compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011024A (en) * 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
GB9625334D0 (en) * 1996-12-05 1997-01-22 Imperial College Compound
GB9118478D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
JPH0912596A (ja) * 1995-06-23 1997-01-14 Meiji Milk Prod Co Ltd 抗癌剤の腫瘍細胞障害作用を増強する新規な蛋白性因子
DE19540233B4 (de) * 1995-10-19 2005-08-25 Schering Ag Sulfamat-Derivate von 1,3,5(10)-Estratrien-Derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO1998011124A1 (fr) * 1996-09-12 1998-03-19 Teikoku Hormone Mfg. Co., Ltd. Derives d'oestrariene a trisubstitution-d-homo-1,3,5,(10)
US5880115A (en) * 1997-07-18 1999-03-09 Duquesne University Of The Holy Ghost Steroid sulfatase inhibitors and methods for making and using the same
GB2331988B (en) * 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
US6046186A (en) * 1997-12-24 2000-04-04 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use

Also Published As

Publication number Publication date
EP1085876B1 (de) 2008-07-23
CA2334119A1 (en) 1999-12-16
AU4280799A (en) 1999-12-30
DE69939171D1 (de) 2008-09-04
ES2310943T3 (es) 2009-01-16
AU765386B2 (en) 2003-09-18
EP1085876A1 (de) 2001-03-28
JP2002517449A (ja) 2002-06-18
US6676934B1 (en) 2004-01-13
CA2334119C (en) 2011-09-13
WO1999064013A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
ATE401896T1 (de) Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
DE69907977D1 (de) Pyrrolobenzodiazepine
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
ATE221887T1 (de) Substituierte 1,2,4-triazolo(3,4,-a)phthalazin- derivate als gaba-alpha 5-liganden
NO20010228L (no) Farmasøytiske preparater omfattende 2-kinoloner
MY124487A (en) Dolastatin derivatives, their preparation and use
DE69329425T2 (de) Dolastatin analog
ATE307204T1 (de) Tumor-nekrose-faktor ähnliches ligand
IT1285770B1 (it) Composti corticoidei
DE69728914D1 (de) Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen
NZ509244A (en) Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine, and/or phenylacetate
BR0113820A (pt) Compostos
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
DK0714387T3 (da) Hidtil ukendte bis-naphthalimider til behandling af cancer
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
DE60239670D1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
FI944563A0 (fi) Mikro-organismeja, valmistusmenetelmä ja käyttö
ES2098338T3 (es) Heteroarilmetilbencenos.
BR0317119A (pt) Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
FI964448A0 (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
TR199900748A2 (xx) Osteinduktif protein ve dorsalize faktörünün kombinasyonunun kullanılması.
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties